KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2025)

Historic EBT Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 18810.88%.

  • CRISPR Therapeutics AG's EBT Margin fell 185927800.0% to 18810.88% in Q4 2025 from the same period last year, while for Dec 2025 it was 17392.93%, marking a year-over-year decrease of 163105100.0%. This contributed to the annual value of 17392.93% for FY2025, which is 163105100.0% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its EBT Margin stood at 18810.88% for Q4 2025, which was down 185927800.0% from 11903.49% recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EBT Margin peaked at 84.75% during Q2 2021, and registered a low of 2022866.67% during Q4 2022.
  • For the 5-year period, CRISPR Therapeutics AG's EBT Margin averaged around 132117.33%, with its median value being 15593.87% (2025).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EBT Margin crashed by 2000000000bps in 2022, and later surged by 2000000000bps in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's EBT Margin (Quarter) stood at 1112.5% in 2021, then plummeted by -181731bps to 2022866.67% in 2022, then skyrocketed by 100bps to 29.43% in 2023, then crashed by -841bps to 218.1% in 2024, then plummeted by -8525bps to 18810.88% in 2025.
  • Its EBT Margin stands at 18810.88% for Q4 2025, versus 11903.49% for Q3 2025 and 23235.09% for Q2 2025.